Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
木曜日, 9 03

ResMed Inc

RMDNYSE
Trade with Public
Trade with Public
$229.19
-1.68-0.73%
近くで: Sep 3, 5:00 PM EST
$229.19
-1.68-0.73%
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

ResMed Financials

ResMed (RMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share from the same period
Benzinga Newsdesk

Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'

Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that disappoint Wall Street.
Tanya Rawat

PRO
ResMed Q3 Adj. EPS $2.86 Beats $2.80 Estimate, Sales $1.431B Beat $1.419B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus estimate of $2.80 by 2.14 percent. This is a 20.68 percent increase over earnings of $2.37 per share from the same period
Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

Analysts Maintain Bull Case On ResMed Despite Competition Concerns

ResMed beat earnings and revenue estimates as sales rose 11% and margins expanded. Analysts backed long-term growth and raised price targets despite competition concerns.
Vandana Singh

Insights into ResMed Q2 Earnings

Benzinga Insights

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved